Skip to main content

Press releases

28/12/25 - 18:48

Diasorin receives FDA 510(k) clearance and CLIA-waiver for its first assay, the 4-Plex Respiratory Panel, on the LIAISON NES Molecular Diagnostics platform (140.92 KB)
Products Molecular
Download

22/12/25 - 17:25

2026 Annual Corporate Events Calendar (117.34 KB)
Other
Download

22/12/25 - 17:18

Publication of documents for the Shareholders’ Meeting to be held on January 27, 2026 (144.42 KB)
Other
Download

22/12/25 - 14:36

The Board of Directors approved to submit to the Shareholders' Meeting the authorization for the purchase and cancellation of treasury shares for the purpose of shareholder remuneration. Ordinary and extraordinary shareholders' meeting convened. (125.84 KB)
Other
Download

24/11/25 - 11:10

Diasorin submits the LIAISON PLEX Gastrointestinal Flex Assay to the U.S. FDA for 510(k) Clearance (128.44 KB)
Products Molecular
Download

18/11/25 - 6:30

Diasorin, in partnership with QIAGEN, unveils the next generation of the LIAISON QuantiFERON-TB Gold Plus II assay to deliver significant testing productivity and faster results in all Countries accepting the CE mark (147.94 KB)
Products Immunodiagnostic
Download

05/11/25 - 17:46

Diasorin’s Board of Directors approves results for the first 9 months of 2025. FY 2025 Guidance revised (255.77 KB)
Financial Data
Download

31/10/25 - 10:12

Diasorin receives 510(k) clearance for Simplexa COVID-19, Flu A/B & RSV Direct kit on the LIAISON MDX from the U.S. Food and Drug Administration (132.55 KB)
Products Molecular
Download

22/10/25 - 7:41

Diasorin signs a supplier agreement with Quest Diagnostics for the innovative molecular multiplexing platform, LIAISON PLEX (125.42 KB)
Molecular
Download

19/09/25 - 9:34

Diasorin launches LIAISON® TSH-R Ab, an immunodiagnostic assay to improve Graves’ Disease diagnosis, in all countries accepting CE mark (130.17 KB)
Products Immunodiagnostic
Download

08/09/25 - 11:16

New evidence on MeMed BV's role in supporting emergency medicine clinical decisions unveiled at ACEP 2025 (136.64 KB)
Products Immunodiagnostic
Download

31/07/25 - 16:22

Revenue Growth and Margin Expansion in H1 2025. FY 2025 Guidance Confirmed (238.17 KB)
Financial Data
Download

02/07/25 - 8:10

Diasorin submits the LIAISON NES® Point-of-Care molecular diagnostics system and 4-plex Respiratory Panel to the FDA for 510(k) Clearance and CLIA Waiver (133.82 KB)
Products Molecular
Download

07/06/25 - 12:25

Diasorin announces 510(k) clearance for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (143.05 KB)
Products Molecular
Download

06/05/25 - 17:41

Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidance (268.56 KB)
Financial Data
Download

28/04/25 - 16:50

Shareholders' Meeting 2025 (138.81 KB)
Other
Download

18/04/25 - 18:11

Diasorin receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX® (161.29 KB)
Products
Download

07/04/25 - 13:07

Publication of the lists of candidates for the appointment of the Board Directors, the Board of Statutory Auditors and relevant proposals for resolution. (111.09 KB)
Financial Disclosures
Download

04/04/25 - 0:59

Notice pursuant to art. 144-octied, para. 2 of CONSOB regulation No. 1971/1999 (125.78 KB)
Other
Download

31/03/25 - 19:36

Adoption of the enhancement of the increased voting rights mechanism: withdrawal exercised by 1.69% of the share capital. Statutory option and pre-emption offer period to start on 31 March 2025. (119.78 KB)
Other
Download

18/03/25 - 11:54

Diasorin launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark (126.65 KB)
Products Molecular
Download

14/03/25 - 16:29

The Board of Directors of Diasorin SpA approves FY2024 Results with revenues and net profit in expansion compared to Previous Year; Proposed Ordinary Dividend of € 1.20 per share (239.79 KB)
Financial Data
Download

03/03/25 - 21:19

Registration and publication the minutes of shareholders' meeting. Withdrawal right. (101.04 KB)
Other
Download

03/03/25 - 21:05

Notice to Shareholders - Information regarding the exercise of the withdrawal right (88.54 KB)
Other
Download

28/02/25 - 11:49

The Extraordinary Meeting of Shareholders approves the enhancement of the increased voting rights mechanism (111.6 KB)
Other
Download

27/01/25 - 20:14

Proposal to enhance the increased voting rights mechanism to support the Company's growth strategy, also by external lines, and reward a shareholder base with a long-term investment horizon (126.5 KB)
Other
Download

01/12/22 - 18:30

2023 Annual Calendar of Corporate Events (288 KB)
Other
Download

09/11/22 - 7:04

DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)
Products Molecular
Download

07/11/22 - 7:12

DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)
Products Molecular
Download

27/10/22 - 13:44

Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)
Financial Data
Download

05/10/22 - 6:37

DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)
Products Molecular
Download

14/09/22 - 0:29

DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)
Products Molecular
Download

03/08/22 - 12:26

Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)
Financial Data
Download

14/07/22 - 20:00

DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)
Products Immunodiagnostic
Download

07/06/22 - 18:06

Execution of the project for the redefinition of the corporate structure of DiaSorin (286.22 KB)
Other
Download

20/05/22 - 7:08

DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)
Products Molecular
Download

09/05/22 - 7:02

DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™ (173.49 KB)
Acquisition / Partnership
Download

06/05/22 - 17:33

Update 2022 Annual Calendar of Corporate Events (285.68 KB)
Financial Disclosures
Download

06/05/22 - 16:45

Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)
Financial Data
Download

02/05/22 - 12:55

Publication of the summary report of the votes cast (280.95 KB)
Financial Disclosures
Download

29/04/22 - 16:26

Shareholders' meeting 2022 (166.12 KB)
Other
Download

22/04/22 - 12:37

New proposal for resolution related to the remuneration of the Board of Statutory Auditors (281.82 KB)
Financial Disclosures
Download

13/04/22 - 16:43

DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative (282.86 KB)
Financial Disclosures
Download

08/04/22 - 19:13

Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution (291.36 KB)
Financial Disclosures
Download

08/04/22 - 9:53

Update annual calendar of corporate events 2022 (288.09 KB)
Financial Disclosures
Download

05/04/22 - 9:51

Notice pursuant to art. 144-octies, paga 2 of Consob Regulation No. 11971/1999 (309.07 KB)
Other
Download

04/04/22 - 18:12

Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l. (577.98 KB)
Other
Download

16/03/22 - 17:39

DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)
Financial Data
Download

08/03/22 - 7:13

DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)
Products Molecular
Download

13/01/22 - 7:24

DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)
Products Molecular
Download
Price Sensitive

eMarket SDIR System and eMarket STORAGE
For the dissemination and the storage of Regulated Information, DiaSorin S.p.A. uses the eMarket SDIR circuit and the eMarket STORAGE mechanism (available at the address www.emarketstorage.it ), managed by Spafid Connect S.p.A., with registered office in Foro Bonaparte, 10, Milan, Italy.